Pyrimethamine
Daraprim, Fansidar, Pyrimethamine (pyrimethamine) is a small molecule pharmaceutical. Pyrimethamine was first approved as Daraprim on 1982-01-01. It is used to treat aids-related opportunistic infections, falciparum malaria, malaria, and toxoplasmosis in the USA. It is known to target multidrug and toxin extrusion protein 2 and multidrug and toxin extrusion protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Pyrimethamine (discontinued: Pyrimethamine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| daraprim | New Drug Application | 2023-12-07 |
| pyrimethamine | ANDA | 2024-01-19 |
| pyrimethamine leucovorin | unapproved drug other | 2015-11-30 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01B: Antimalarials
— P01BD: Diaminopyrimidines, antimalarials
— P01BD01: Pyrimethamine
— P01BD51: Pyrimethamine, combinations
— P01BF: Artemisinin and derivatives, combinations
— P01BF04: Artesunate, sulfalene and pyrimethamine
— P01BF09: Artesunate, sulfadoxine and pyrimethamine
HCPCS
No data
Clinical
Clinical Trials
212 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 10 | 19 | 59 | 31 | 52 | 157 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 5 | 14 | 8 | 13 | 38 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 5 | 6 | 15 | 26 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 4 | 3 | 1 | 7 | 17 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 5 | 3 | 5 | 14 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | 3 | 3 | — | 2 | 4 | 12 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 1 | 1 | 2 | 4 | 9 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 2 | 1 | 3 | 7 |
| Birth weight | D001724 | EFO_0004344 | — | — | — | — | 2 | 2 | 4 |
| Communicable diseases | D003141 | — | — | — | — | — | 2 | 2 | 4 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | 1 | 3 | — | 2 | 6 |
| Parasitemia | D018512 | — | — | 1 | 1 | 1 | — | 1 | 4 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | 2 | — | — | 3 |
| Aids-related opportunistic infections | D017088 | — | — | — | — | 1 | — | 2 | 3 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | 2 | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | 1 | — | — | 2 |
| Only child | D009863 | — | — | — | — | 2 | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | 1 | 2 |
| Schistosoma mansoni | D012550 | NCBITaxon_6183 | — | — | — | 1 | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | — | — | 1 | — | — | 1 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral toxoplasmosis | D016781 | EFO_0007200 | B58.2 | 2 | 3 | — | — | 4 | 9 |
| Encephalitis | D004660 | — | — | 2 | 1 | — | — | 4 | 7 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | — | — | 2 | 3 |
| Tay-sachs disease | D013661 | Orphanet_845 | E75.02 | 2 | 1 | — | — | — | 2 |
| Sandhoff disease | D012497 | Orphanet_796 | E75.01 | 2 | 1 | — | — | — | 2 |
| Gangliosidoses | D005733 | — | E75.10 | 2 | 1 | — | — | — | 2 |
| Gm2 gangliosidoses | D020143 | Orphanet_309152 | E75.0 | 2 | 1 | — | — | — | 2 |
| Vaso-occlusive crises | D000098644 | — | — | 1 | 1 | — | — | — | 1 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | — | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 2 | — | — | — | — | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 2 | — | — | — | — | 2 |
| Autoimmune lymphoproliferative syndrome | D056735 | — | D89.82 | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Lymphatic diseases | D008206 | — | — | 1 | — | — | — | — | 1 |
| Lymphadenopathy | D000072281 | — | R59.1 | 1 | — | — | — | — | 1 |
| Splenomegaly | D013163 | — | R16.1 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 6 | 6 |
| Growth disorders | D006130 | — | — | — | — | — | — | 2 | 2 |
| Severe acute malnutrition | D000067011 | — | — | — | — | — | — | 2 | 2 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | — | 1 | 1 |
| Fever | D005334 | — | R50.9 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 1 | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | — | — | 1 | 1 |
| Behavior | D001519 | GO_0007610 | STY/T053 | — | — | — | — | 1 | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 1 | 1 |
| Child development | D002657 | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pyrimethamine |
| INN | pyrimethamine |
| Description | Pyrimethamine is an aminopyrimidine that is pyrimidine-2,4-diamine which is substituted at position 5 by a p-chlorophenyl group and at position 6 by an ethyl group. It is a folic acid antagonist used as an antimalarial or with a sulfonamide to treat toxoplasmosis. It has a role as an antimalarial, an EC 1.5.1.3 (dihydrofolate reductase) inhibitor and an antiprotozoal drug. It is an aminopyrimidine and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 58-14-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL36 |
| ChEBI ID | 8673 |
| PubChem CID | 4993 |
| DrugBank | DB00205 |
| UNII ID | Z3614QOX8W (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Pyrimethamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,372 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use